Download MendeleyEsomeprazole covalently interacts with the cardiovascular enzyme dimethylarginine dimethylaminohydrolase: Insights into the cardiovascular risk of proton pump inhibitors.
Smith, C.A., Ebrahimpour, A., Novikova, L., Farina, D., Bailey, A.O., Russell, W.K., Jain, A., Saltzman, A.B., Malovannaya, A., Prasad, B.V.V., Hu, L., Ghebre, Y.T.(2022) Biochim Biophys Acta Gen Subj 1866: 130149-130149
- PubMed: 35472493
- DOI: https://doi.org/10.1016/j.bbagen.2022.130149
- Primary Citation of Related Structures:
7USZ, 7UT0 - PubMed Abstract:
Proton pump inhibitors (PPIs) are widely prescribed drugs for the treatment of gastroesophageal reflux disease (GERD). Several meta-analysis studies have reported associations between prolonged use of PPIs and major adverse cardiovascular events. However, interaction of PPIs with biological molecules involved in cardiovascular health is incompletely characterized. Dimethylarginine dimethylaminohydrolase (DDAH) is a cardiovascular enzyme expressed in cardiomyocytes, and other somatic cell types in one of two isotypes (DDAH1 and DDAH2) to metabolize asymmetric dimethylarginine (ADMA); a cardiovascular risk factor and competitive inhibitor of nitric oxide synthases (NOSs).
Organizational Affiliation:
Stanford Synchrotron Radiation Lightsource, SLAC National Accelerator Laboratory, Stanford University, Menlo Park, CA 94025, USA; Department of Chemistry, Stanford University, Stanford, CA 94305, USA. Electronic address: csmith@slac.stanford.edu.
